Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis

Conklin, L. S.; Merkel, P. A.; Pachman, L. M.; Parikh, H.; Tawalbeh, S.; Damsker, J. M.; Cuthbertson, D. D.; Morgan, G. A.; Monach, P. A.; Hathout, Y.; Nagaraju, K.; van den Anker, J.; McAlear, C. A.; Hoffman, E. P.

Steroids. 2018 Oct 24; 140:159-166

Abstract

Glucocorticoids are standard of care for many chronic inflammatory conditions, including juvenile dermatomyositis (JDM) and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We sought to define pharmacodynamic biomarkers of therapeutic efficacy and safety concerns of glucocorticoid treatment for these two disorders. Previous proteomic profiling of patients with Duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD) treated with glucocorticoids identified candidate biomarkers for efficacy and safety concerns of glucocorticoids. Serial serum samples from patients with AAV (n=30) and JDM (n=12) were obtained during active disease, and after treatment with glucocorticoids. For AAV, 8 of 11 biomarkers of the anti-inflammatory response to glucocorticoids were validated (P-value

Read More on PubMed